Remibrutinib lowers relapse activity in relapsing multiple sclerosis, but not as far as a Roche rival
Novartis’ remibrutinib has moved into the center of the multiple sclerosis debate with Phase 3 data showing a meaningful reduction in relapse activity against Sanofi’s Aubagio in relapsing disease. The drug cut the annualized relapse rate by 35.2% in one pivotal study and by 31.2% in the other, a degree of efficacy that places it below Roche’s competing BTK inhibitor, fenebrutinib, but still within the range that could matter clinically if its tolerability holds up in longer use.
Heinz Wiendl, a neurologist at the University of Freiburg, presented the findings from the REMODEL-1 and REMODEL-2 trials at an MS conference in Toronto. He framed the reduction in relapses in a way clinicians immediately understand: the effect was roughly equivalent to about one relapse every 13 years. In a relapsing disease where repeated inflammatory attacks can accumulate disability over time, even incremental reductions in relapse burden can affect treatment sequencing, especially when safety, convenience, and patient adherence enter the decision.
The relapse signal sits below Roche’s efficacy, but the safety tradeoff could still shape adoption
The comparison with fenebrutinib is impossible to ignore. Roche’s drug, in its own pivotal studies, reduced relapse rates by more than 50% versus Aubagio, placing it ahead on raw efficacy. Yet clinical prescribing rarely turns on efficacy alone. In relapsing MS, BTK inhibitors are being judged not only on their ability to suppress inflammatory relapses, but also on whether they can do so without creating a safety burden that limits real-world use over years of therapy.
Remibrutinib’s cleaner safety profile may become its most important commercial and clinical asset. A lower adverse-event burden can matter as much as a modest efficacy gap when a disease demands chronic treatment and patients are weighing long-term exposure rather than short-term rescue. For neurologists, the central question is not whether the drug works in principle — these trials show that it does — but whether a slightly less potent relapse reduction can be offset by better tolerability, more comfortable monitoring, or easier persistence on treatment.
The underlying biology makes the class attractive. BTK inhibition targets pathways involved in B-cell signaling and innate immune activation, both of which contribute to the inflammatory cascade in multiple sclerosis. By dampening those signals upstream, the approach aims to reduce the immune attacks that drive clinical relapses and MRI activity. In relapsing MS, where inflammatory events can translate into cumulative neurologic injury, a therapy that suppresses that immune traffic without the safety liabilities of older immunosuppressive strategies would have obvious appeal.
Phase 3 efficacy in REMODEL-1 and REMODEL-2 was consistent across both studies
The most straightforward reading of the REMODEL program is consistency. Two separate Phase 3 studies produced annualized relapse rate reductions of 35.2% and 31.2% versus Aubagio, which argues against a one-off statistical fluke or a trial-specific artifact. The data also suggest that remibrutinib lands in a meaningful therapeutic zone rather than at the margins of biologic effect.
Relapse reduction remains one of the most tangible endpoints in relapsing MS because it maps onto events patients and clinicians recognize immediately: new neurologic symptoms, functional setbacks, steroid treatment, and anxiety over future disability. A therapy that cuts relapse frequency can reduce these disruptions even before longer-term disability outcomes are fully known. In practical terms, a lower annualized relapse rate can mean fewer acute care visits, fewer treatment escalations, and less cumulative inflammatory injury over time.
Still, the magnitude of effect matters. A 31% to 35% reduction is clinically meaningful, but it is not class-leading in a field now crowded with increasingly potent immune therapies. The comparison with fenebrutinib gives remibrutinib a clear benchmark, and that benchmark is higher than the one Novartis delivered here. For physicians, the result will likely be interpreted less as a question of whether the drug belongs in the conversation and more as a question of where it belongs within the treatment sequence.
Why a cleaner safety profile may matter as much as relapse reduction
A relapse-rate cut of this size does not automatically guarantee market success. MS specialists have learned repeatedly that patients and clinicians tolerate efficacy gaps poorly when safety is uncertain, but they also accept slightly lower efficacy if the treatment is easier to live with over years. That calculus grows sharper in relapsing MS because treatment decisions are often made early, when patients are young, active, and highly sensitive to the prospect of long-term adverse effects.
BTK inhibitors also occupy a strategically important place in the MS pipeline because they promise oral dosing and targeted immune modulation without some of the burdens tied to infusion-based therapies or broader immunosuppression. If remibrutinib maintains the cleaner safety profile implied by the conference presentation, the drug could still carve out a competitive role, particularly for patients and clinicians who value tolerability and a more modest safety-monitoring burden alongside relapse control.
The present data do not settle the longer-term durability question. Phase 3 relapse results are a major milestone, but they do not by themselves define how a drug will perform across years of real-world use, nor do they fully capture comparative value against newer agents with stronger efficacy signals. What they do establish is that remibrutinib has crossed a central efficacy threshold in relapsing MS and has done so with enough consistency across two studies to remain in contention.
Competitive pressure in relapsing MS now turns on where efficacy and tolerability intersect
The therapeutic race in relapsing MS is increasingly defined by tradeoffs. Roche’s fenebrutinib appears to be ahead on relapse suppression, while Novartis now has a differentiated safety narrative that could still resonate with prescribers. In a market shaped by chronic treatment, adverse-event management, and patient preferences, the better drug is not always the one with the largest numerical effect size on a conference slide.
For now, the most concrete clinical takeaway is narrow and data-driven: remibrutinib reduced annualized relapse rates in two Phase 3 trials against Aubagio, but the efficacy trail it leaves is shorter than fenebrutinib’s. The next questions are not abstract. They concern how the full safety dataset looks in practice, whether the benefit persists over longer follow-up, and where neurologists decide to position another oral option in an increasingly crowded MS armamentarium.